Double-blind, randomised, controlled trial assessing controller medications in asthma

Respiration

Volumn 73, Issue 4, 2006, Pages 449-456

  Shah, A R ^a,b   Sharples, L D ^a   Solanki, R N ^a   Shah, K V ^a  

^a CIVIL HOSPITAL   (India)

^b NONE   (United Kingdom)

Author keywords

Asthma; Chronic asthma; Montelukast; Steroids; Theophylline

Indexed keywords

BUDESONIDE; MONTELUKAST; PLACEBO; STEROID; THEOPHYLLINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EXPIRATORY FLOW RATE; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HUMAN; LOW DRUG DOSE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MODERATE PERSISTENT ASTHMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SORE THROAT; SUSTAINED DRUG RELEASE;

ACETATES; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; PATIENT SELECTION; QUINOLINES; THEOPHYLLINE;

EID: 33745201894     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090898     Document Type: Article

References (34)

1. Scadding JG: Definition and clinical categories of asthma; in Clark TJH, Godfrey S (eds): Asthma, ed 2. London, Chapman & Hall, 1983, chap 1.
2. Barnes PJ: Inhaled glucocorticosteroids for asthma. N Engl J Med 1995;332:868-875.
3. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RF: Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996;153:1739-1748.
4. Barnes PJ, Jonsson B, Klim JP: The cost of asthma. Eur Respir J 1996;9:636-642.
5. National Asthma Education, and Prevention Program (April 1997): Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, National Institutes of Health, Publication No. 97-4051.
6. Woolcock A, Lundback B, Ringdal N, Jacques LA: Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-1488.
7. Hendeles L, Harman E, Huang D, O'Brien R, Blake K, Delafuente J: Theophylline attenuation of airway responses to allergen: comparison with cromolyn metered-dose inhaler. J Allergy Clin Immunol 1995;95:505-514.
8. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J: Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-1008.
9. Magnussen H, Reuss G, Jorres R: Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics. Am Rev Respir Dis 1987;136:1163-1167.
10. Terao I: Effects of once-daily low-dose administration of sustained-release theophylline on airway inflammation and airway hyperresponsiveness in patients with asthma. Arerugi 2002;51:364-370.
11. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, Reiss TF: A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 1998;102:50-56.
12. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, Reiss TF: Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 1998;11:1232-1239.
13. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB: Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-1220.
14. Ducharme F, Schwartz Z, Kakuma R: Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. The Cochrane Database of Systematic Reviews. Chichester, Wiley, 2005, issue 2.
15. Price DB, Hernandez D, Magyar P, et al: Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-216.
16. 2 agonists. Edinburgh, Scottish Intercollegiate Guidelines Network, 2002. http://www.sign.ac.uk/guidelines/published/support/ guideline63/index.html.
17. 2 agonist therapy in asthma. Am J Respir Crit Care Med 2001;164:923-932.
18. 2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. The Cochrane Database of Systematic Reviews, issue 2. Hoboken, Wiley, 2005.
19. Vaquerizo MJ, Casan P, Castillo J, et al: Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-210.
20. Dempsey O, Fowler S, Wilson A: Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002;122:151-159.
21. Higgins BG, Douglas JG: The new BTS/SIGN asthma guidelines: where evidence leads the way. Thorax 2003;58:98-99.
22. National Institutes of Health: Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. Bethesda, National Heart, Lung and Blood Institute, 2002.
23. 4 excretion. Am Rev Respir Dis 1993;147:142-146.
24. Dworski R, Fitzgerald GA, Oats JA, et al: Effect of oral prednisolone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-959.
25. Laviolette M, Malmstrom K, Lu S, et al: Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-1868.
26. Virchow CJ, Prasse A, Naya I, et al: Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:578-585.
27. 2-adrenoceptor genotype. Am J Med 2000;109:114-121.
28. Yurdakul AS, Taci N, Eren A, Sipit T: Comparative efficacy of once-daily therapy with inhaled corticosteroid, leukotriene antagonist or sustained-release theophylline in patients with mild persistent asthma. Respir Med 2003;97:1313-1319.
29. Greening AP, Ind PW, Northfield M, Shaw G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-224.
30. Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-1411.
31. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ: A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-1418.
32. Virchow CJ, Prasse A, Naya I, Summerton L, Harris A: Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:578-585.
33. Ceylan E, Gencer M, Aksoy S: Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control. Respiration 2004;71:594-601.
34. Altman LC, Munk Z, Seltzer J, et al: A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 1998;102:50-56.